The NHMRC Genomics Targeted Call for Research Grant Advisory Committee (the Advisory Committee) has been established to oversee the progress of the $25 million Genomics Grant awarded in October 2015, for the duration of the grant.
The Advisory Committee is comprised of experts in genomic medicine, and experts in areas of health and medical research where genomics is becoming increasingly important.
Current appointments to the Genomics Targeted Call for Research Grant Advisory Committee are from 1 January 2016 to 31 December 2018.
The Advisory Committee will meet bi-annually to assess progress against identified milestones, as well as the grant holders’ participation in, and compliance with, the objectives of the Global Alliance for Genomics and Health) and the Global Genomic Medicine Collaboration. Grant recipients are required to submit a progress report against the milestones outlined in their Research Proposal to the Advisory Committee for assessment at these meetings. The Advisory Committee will advise NHMRC’s CEO on whether milestones have been met.
Terms of Reference
The Terms of Reference for the Genomics Targeted Call for Research Grant Advisory Committee are to:
- Assess progress of the Genomics TCR grant against six-monthly milestones.
- Assess the grant holders’ participation in, and compliance with, the objectives of the Global Alliance for Genomics and Health and the Global Genomic Medicine Collaboration.
- Recommend adjustments to the budget of the grant based on progress against the milestones.
- Perform other duties as directed by the NHMRC’s Chief Executive Officer.
Member information and Declarations of Interest
The members of the expert Advisory Committee were required to document their interests and involvement (financial and non-financial) in activities regarding health and medical research. The members were also asked to consider perceived conflicts of interest as well as real interests.
Centre for Reproductive Health
Hudson Medical Research Institute
- Honorary Life Member of the Endocrine Society of Australia.
- Emeritus Member & Fellow of the Society for the Study of Reproduction, USA.
- Lifetime Member & Fellow of the Society for Reproductive Biology.
- Honorary Professor of Obstetrics and Gynaecology, University of Melbourne.
- Adjunct Professor at the Monash University Faculty of Medicine, Nursing and Health Sciences.
- Chair of the Robinson Research Institute Advisory Board, University of Adelaide
- Previous NHMRC SPRF and Project and Program Grant holder
Professor Findlay is internationally recognised for his research into female reproduction and fertility, which has led to a shift in understanding how hormones have local effects on the body including the production of eggs, and to the development of improved IVF procedures. Professor Findlay’s recent research has contributed to our understanding of chemoresistance and metastasis of ovarian cancer.
Professor Findlay has no declared interests.
Director of Bioinformatics and Genome Analysis, Genomics England
Queen Mary University of London
- Senior Research Associate at the University of Cambridge Department of Haematology.
- Researcher at the Medical Research Council Biostatistics Unit.
Professor Rendon is internationally recognised for his work leading the UK’s 100,000 Genomes Project, and the design of genome interpretation systems for use by the UK’s National Health Service. Professor Rendon’s recent work has focussed on the building of genomic databases to enable translation research within the programs he leads.
Professor Rendon currently works for Genomics England Ltd, which has a pre-existing affiliation with the Garvan Institute of Medical Research in areas related to parts of the research proposed for the Genomics Targeted Call for Research Grant. There is no active collaboration at this stage, however there is potential for the grantees to form one with Genomics England in the future.
Director of the Centre for Therapeutic Target Validation, Wellcome Trust Sanger Institute
- Helped to design the first generation of genome-wide association studies (GWAS).
- Lead analyst for the Wellcome Trust Case Control Consortium.
- Co-Chair of the International Inflammatory Bowel Disease Genetics Consortium.
- Management Committee member for Wellcome Trust Case Control Consortium 3 studies.
- Management Committee member for the Deciphering Developmental Disorders project.
- Management Committee member for UK10K – Rare Genetic Variants in Health and Disease project
Professor Barrett is internationally recognised for his efforts in exploring the overlapping genetic architecture of diseases of inflammation, immunity, and infection including celiac disease, inflammatory bowel disease, multiple sclerosis, tuberculosis and malaria. Professor Barrett's recent work relates to his team’s analysis of large-scale exome-sequencing datasets to probe the contribution of rare genetic variation in developmental disorders, autism and schizophrenia.
Professor Barrett has no declared interests.
Chief Medical Officer and Chief Public Health officer of South Australia
- Professor and former Head of Medicine, Flinders University, Flinders Medical Centre and Repatriation General Hospital in Adelaide.
- Held tenured senior academic positions at Universities of Melbourne and Oxford and is Adjunct professor of Medicine at Duke University, USA.
Professor Phillips is nationally recognised for his research and efforts in building a better health system through innovation, collaboration and leadership. He remains clinically active in Acute General Medicine.
Professor Phillips has no declared interests.
Professor of Medicine, Sydney Medical School
The George Institute for Global Health
- Chief Scientist of the George Institute for Global Health.
- Cardiologist and Honorary Senior Medical Officer at the Royal Prince Alfred Hospital.
- Fellow and Council Member, Australian Academy of Health and Medical Sciences.
- NHMRC Elizabeth Blackburn Fellow
Professor Patel is internationally recognised for her focus on developing innovative solutions for delivering affordable and effective chronic disease care in the community and in acute care hospital settings. Professor Patel's recent research covers the treatment of Type 2 Diabetes in Australia, India and China.
Professor Patel has no declared interests.